The complaint, filed by the DJS Law Group, targets violations of the Securities Exchange Act of 1934 between March 24, 2025, and March 12, 2026. Plaintiffs allege that Immutep issued false assurances in an SEC Form-K filing on January 30, 2026, describing the trial as showing strong operational progress. The lawsuit asserts that company executives were aware at the time that the trial would fail to meet its primary efficacy endpoints, misleading investors who relied on these public statements.
Investors Launch Class Action Against Immutep Over Clinical Trial Claims
Shareholders of Immutep Limited are facing a July 6, 2026, deadline to join a class action lawsuit alleging the company misled the market regarding the efficacy of its TACTI-004 clinical trial. The litigation centers on claims that leadership concealed known failures while publicly touting the progress of its drug, eftilagimod alfa.
Investors who purchased shares during this period are encouraged to contact David J. Schwartz of the DJS Law Group. While the firm is seeking lead plaintiffs to head the action, participation in a potential recovery does not strictly require such an appointment. The suit specifically cites breaches of sections 10(b) and 20(a) of the Securities Exchange Act, alongside Rule 10b-5, as the legal foundation for the claim.
Comments (0)
No comments yet. Be the first!